US006403562B1

(12) **United States Patent**
Johnson et al.

(10) **Patent No.: US 6,403,562 B1**
(45) **Date of Patent: Jun. 11, 2002**

(54) **MATERIALS AND METHODS FOR TREATING AUTOIMMUNE DISEASE**

(75) Inventors: **Howard M. Johnson**; **Mustafa G. Mujtaba**, both of Gainesville, FL (US); **Jeanne M. Soos**, Watertown, MA (US)

(73) Assignee: **University of Florida**, Gainesville, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/361,724**

(22) Filed: **Jul. 27, 1999**

Related U.S. Application Data

(63) Continuation of application No. 08/986,063, filed on Dec. 5, 1997, now Pat. No. 6,083,919.

(60) Provisional application No. 60/032,617, filed on Dec. 5, 1996, now abandoned.

(51) **Int. Cl.**[7] **A61K 38/00**; A61K 38/21; A01N 37/18; C07K 1/00; C07K 14/00

(52) **U.S. Cl.** **514/21**; 514/3; 514/12; 530/350; 530/351; 424/84.5; 424/84.6; 424/184.1

(58) **Field of Search** 514/2, 12, 21; 530/351, 350, 324; 424/85.4, 85.6, 85.2, 184.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,083,919 A * 7/2000 Johnson et al. 514/21

FOREIGN PATENT DOCUMENTS

WO 9628183 9/1986

OTHER PUBLICATIONS

The Merck Manual, Berkow R., Editor, 16th ed., Merck & Co; Inc., pp. 339–342, 1992.*

Chaouat, G., Assal–Meliani, A., Martal, J., Raghupathy, R., Elliot, J., Mosmann, T. and Wegmann, T.G. (1995) "IL10 prevents naturally occurring fetal loss in the CBA X DBA/2 mating combinations, and local defect in IL10 production in this abortion–prone combination is corrected by in vivo injection of IFN_T" *J. Immunmol.* 154:4261–4268.

Johns, L.T., Flanders, K.C., Ranges, G.E. and Sriram, S. (1991) "Successful treatment of experimental allergic encehalomyelitis with transforming growth factor–β1" *J. Immunmol.* 147:1792–1796.

Johnson, H.M. and Blalock, J.E. (1980) "Interferon immunosuppression: mediation by a suppressor factor" *Infect. Immun.* 29:301–305.

Massague, J. (1990) "The transforming growth factor–β family" *Annu. Rev. Cell. Biol.* 6:597.

Moore, K.W., Vieira, P., Fiorentino, D.F., Trounstine, M.L., Khan, T.A., and Mosmann, T.R., (1990) "Homology of cytokine synthesis inhibitory factor (IL–10) to the Epstein–Barr virus gene BCRF1" *Science* 248:1230.

Rott, O., Fleischer, B. and Cash, E. (1994) "Interleukin–10 prevents experimental allergic encephalomyelitis in rats" *Eur. J. Immunol.* 24:1434–1440.

Schluesener, H.J. and Lider, O. (1989) "Transforming growth factors β1 and β2: Cytokines with identical immunosuppressive effects and potential role in the regulation of autoimmune T cell function" *J. Neuroimmunol.* 24:249–258.

Soos, J.M., Subramaniam, P.S., Hobeika, A.C., Schiffenbauer, J. and Johnson, H.M. (1995) "The IFN pregnancy recognition hormone, interferon tau, blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity" *J. Immunol.* 155:2747–2753.

Stevens, D.B., Gould, K.E. and Swanborg, R.H. (1994) "Transforming growth factor–beta 1 inhibits tumor necrosis factor–alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis" *J. Neuroimmunol.* 51:77–83.

Viera, P., de Waal Malefyt, R., Dang, M.–N., Johnson, K.E., Kastelein, R., Fiorentino, D.F., de Vries, J.E., Roncarolo, M.–G., Mosmann, T.R., and Moore, K.W. (1991) "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein–Barr virus open reading frame BCRF1" *Proc. Natl. Acad. Sci.* 88:1172.

Zamvil, S.S. and Steinman, L. (1990) "The T lymphocyte in experimental allergic encephalomyelitis" *Annu. Rev. Immunol.* 8:579–621.

Chen, Y. Inobe, J., Weiner, H.L. (1995) "Induction of Oral Tolerance to Myelin Basic Protein in CD8–Depleted Mice" *Journal of Immunology* 155:910–916.

Reitamo, S. et al. (1992) "Interleukin 10 up–regulates elastin gene expression in vivo and in vitro at the transcription level" *Biochemical Journal* 302:331–333.

Oswald, I.P. et al. (1992) "IL–10 synergizes with IL–4 and transforming growth factor–β to inhibit macrophage cytotoxic activity" *Journal of Immunology* 148:3578–3582.

Karpus, W. J., Swanborg, R.H. (1991) CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor–β *Journal of Immunology* 146:1163–1168.

Weckmann, A.L., Alcocer–Varela, J. (1996) Cytokine Inhibitors in Autoimmune Disease Seminars in Arthritis and Rheumatism 26(2):539–557.

* cited by examiner

Primary Examiner—Avis M. Davenport
(74) *Attorney, Agent, or Firm*—Saliwanchik, Lloyd & Saliwanchik

(57) **ABSTRACT**

The subject invention pertains to novel methods for treating autoimmune-related diseases, such as Multiple Sclerosis (MS). One embodiment of the method of the invention comprises administering interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), in combination, to a person afflicted with or predisposed to an autoimmune disease. When administered in combination, these cytokines act in a synergistic manner as suppressor factors to inhibit the activation of self-reactive T cells that are involved in autoimmune disease.

6 Claims, 8 Drawing Sheets